Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06464588 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)
A Phase 1 study of Dilated Cardiomyopathy, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 5
- Study locations
NCT06464588 is a Phase 1 study of Dilated Cardiomyopathy that is actively recruiting participants, run by Emory University. The registered enrollment target is 36 participants, below the 257-participant average among 6 other Dilated Cardiomyopathy trials with a reported enrollment target (86% lower). The trial reports 5 study locations across 1 state.
The verdict
NCT06464588, a Phase 1 study of Dilated Cardiomyopathy, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase 1 study to determine the safety and efficacy of allogeneic neonatal mesenchymal stromal cells (nMSCs) for the treatment of Dilated Cardiomyopathy. The purpose of the study is to help doctors and scientists learn if allogeneic neonatal mesenchymal stromal cells (nMSCs) infusions are a safe and effective way to improve cardiac function and left ventricular ejection fraction.
Conditions Studied
Interventions
- BIOLOGICAL Allogeneic Neonatal mesenchymal stromal cells (nMSCs)
Study Locations (5)
Georgia
- Hughes Spalding Children's Hospital - Atlanta
- Egleston Children's Hospital - Atlanta
- Emory Children's Center - Atlanta
- Emory University Hospital - Atlanta
- Scottish Rite Children's Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-07-14 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06464588
The ClinicalTrials.gov registry entry for NCT06464588 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 6 other Dilated Cardiomyopathy trials with a reported enrollment target (86% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dilated Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which Allogeneic Neonatal mesenchymal stromal cells (nMSCs) is the first listed.
NCT06464588 reports 5 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06464588 about?
NCT06464588 is a clinical study titled "A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)". This is a Phase 1 study to determine the safety and efficacy of allogeneic neonatal mesenchymal stromal cells (nMSCs) for the treatment of Dilated Cardiomyopathy. The purpose of the study is to help doctors and scientists learn if allogeneic neonatal mesenchymal stromal cells (nMSCs) infusions are a...
What is the current status of trial NCT06464588?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2025-07-14. Estimated completion is 2027-07.
What conditions does trial NCT06464588 study?
This clinical trial studies the following conditions: Dilated Cardiomyopathy.
What interventions are being tested in trial NCT06464588?
The interventions under investigation include: Allogeneic Neonatal mesenchymal stromal cells (nMSCs) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06464588?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06464588 being conducted?
This trial has 5 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dilated Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)
RECRUITING · NA
-
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
RECRUITING · NA
-
Dilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Ancillary Study
RECRUITING
-
Pediatric Cardiomyopathy Mutation Analysis
RECRUITING
-
Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy
COMPLETED · Phase 2
-
Nesiritide - Dilated Cardiomyopathy
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.